AstraZeneca has extended its cardiorenal pipeline with a $1.3 billion acquisition of CinCor Pharma, adding a late-stage blood pressure-lowering drug. The $26-per-share upfront deal focuses on ...
In this episode of the pharmaphorum podcast, editor-in-chief Jonah Comstock welcomes Marc de Garidel, CEO of CinCor Pharma, which was just recently sold to AstraZeneca for more than $1 billion USD.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback